Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 39.6 Cr.
- Current Price ₹ 43.0
- High / Low ₹ 65.8 / 25.4
- Stock P/E
- Book Value ₹ 15.4
- Dividend Yield 0.00 %
- ROCE -28.0 %
- ROE -89.5 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.73 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -13.4%
- Promoter holding is low: 15.9%
- Company has a low return on equity of -21.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| -0 | 243 | 191 | 212 | 151 | 75 | 57 | |
| 0 | 235 | 178 | 205 | 143 | 91 | 69 | |
| Operating Profit | -0 | 8 | 13 | 8 | 7 | -16 | -12 |
| OPM % | 3% | 7% | 4% | 5% | -22% | -20% | |
| -0 | 0 | 0 | 0 | 0 | 2 | 1 | |
| Interest | -0 | 3 | 2 | 3 | 5 | 4 | 5 |
| Depreciation | -0 | 2 | 2 | 2 | 3 | 2 | 3 |
| Profit before tax | -0 | 4 | 9 | 2 | 0 | -21 | -17 |
| Tax % | -0% | 56% | 29% | 38% | -183% | -3% | |
| -0 | 2 | 7 | 1 | 1 | -20 | -17 | |
| EPS in Rs | -0.24 | 1.93 | 7.20 | 1.36 | 1.12 | -21.90 | -18.12 |
| Dividend Payout % | -0% | -0% | 14% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -27% |
| TTM: | -49% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -307% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -9% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | -22% |
| Last Year: | -89% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.41 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | -0 | 17 | 24 | 24 | 26 | 5 | 5 |
| -0 | 12 | 27 | 31 | 44 | 40 | 43 | |
| -0 | 70 | 74 | 51 | 38 | 40 | 34 | |
| Total Liabilities | 0 | 109 | 133 | 116 | 117 | 95 | 91 |
| -0 | 20 | 21 | 27 | 27 | 25 | 24 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 89 | 112 | 89 | 90 | 69 | 66 | |
| Total Assets | 0 | 109 | 133 | 116 | 117 | 95 | 91 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -0 | 27 | 8 | -10 | -7 | 11 | |
| -0 | -8 | -4 | -7 | -2 | -3 | |
| -0 | 19 | 12 | 0 | 8 | -8 | |
| Net Cash Flow | -0 | 38 | 16 | -16 | -0 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 69 | 60 | 77 | 64 | |
| Inventory Days | 73 | 109 | 98 | 158 | 260 | |
| Days Payable | 114 | 161 | 74 | 103 | 175 | |
| Cash Conversion Cycle | 23 | 17 | 84 | 131 | 150 | |
| Working Capital Days | 14 | -19 | 21 | 28 | -37 | |
| ROCE % | 34% | 23% | 9% | 7% | -28% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Nov
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Nov
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Nov
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Nov
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Nov
Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.